T cell-based immunotherapy for advanced non-small cell lung cancer

T cell-based immunotherapy technology for advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-13003669

Enrollment

Unknown

Registered

2013-08-24

Start date

2013-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

treatment group:Radiotherapy

chemotherapy

immunotherapy

control group:Radiotherapy

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: Non-small Lung cancer was diagnosed based on imaging studies and pathology; TNM stage of tumor is ?B or IV; no chance to operat. No acute and serious complications, including bleeding,organ failure, older than 18 years.

Exclusion criteria

Exclusion criteria: Autoimmune diseases; severe allergic or adverse reactions; syphilis, AIDS, failure of important organs, uncontrolled diabetes.

Design outcomes

Primary

Measure	Time frame
tumour;	—

Secondary

Measure	Time frame
tumor markers;Flow cytometry;TCR;Progression-free survival;	—

Countries

China

Contacts

Public ContactDong Ming-Xin

The General Hospitol of JiLin Chemical Company

839409586@qq.com+86 13804412605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026